BioSpace News Archive

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the first participants in the Phase 1/2 MARINA trial have been dosed with Avidity’s lead AOC product candidate, AOC 1001, marking the first time a person has been dosed with an AOC.

EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces the appointment of Dr. Marwan Sabbagh as non-executive director to its Board of Directors with immediate effect.

BeiGene announced clinical results and real world data from its hematology program to be presented at the 63rd American Society of Hematology Annual Meeting and Exposition, including two oral presentations on the Phase 3 SEQUOIA trial comparing BRUKINSA® to bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

Xencor, Inc. today announced that updated clinical data from its Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell malignancies will be presented in a poster session during the 63rd American Society Annual Meeting

Vor Biopharma, a clinical-stage cell and genome engineering company, announced the upcoming presentation of new data from its novel engineered hematopoietic stem cell platform at the American Society of Hematology 63rd Annual Meeting, taking place in Atlanta, Georgia from December 11-14, 2021.

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced a topline summary of the presentations planned for 2021 R&D Day virtual event, which begins at 11:00 AM ET.

Incyte announced that numerous abstracts highlighting data from its oncology portfolio will be presented at the upcoming 63rd American Society of Hematology Annual Meeting and Exposition, held December 11–14, 2021 in Atlanta, Georgia and virtually.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Founder, Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will deliver a company presentation at the 2021 Jefferies London Healthcare Conference, which is being held November 16-18, 2021.

Rheos Medicines today announced it will present preclinical data showing the potential for MALT1 inhibitors for the treatment of chronic Graft-Versus-Host Disease (GVHD) at the 63rd Annual Meeting of the American Society of Hematology (ASH)